Replies to post #773427 on NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Thanks, Doc Logic, appreciate the thoughtful expansion. Just to clarify, I wasn’t referencing Fraunhofer or German regulatory restrictions specifically, but I agree with your broader point: once statistical sufficiency was reached, continuing SOC-only enrollment would have raised ethical concerns. I also completely agree that artisan manufacturing was never viable for a scalable platform, and the recent regulatory shifts (like PICV and IFR) are finally aligning with what the platform was always designed to be.

[ilovetech]

Doc Logic - Speaking of ethical, it's unethical to string a cash strapped pre-revenue biotech along for 15 months, especially if true, that the MHRA milked dcvax, as it's regulatory model to build a framework around. It's been an unconscionable one sided affair. How convenient, NWBO paid these morons a huge application fee, and helped the regulator with their homework. Where's the reciprocity? NWBO is not a charity. Was NWBO leveled with the entire time, three years, to see the application submitted, that at the end of the day the regulator wasn't prepared to handle the application for whatever their shortcomings were at the time? That's not Ok. The reviewers were paid their salaries the entire time, and the only thing NWBO received in return is dangling carrots. Nothing but doublespeak, and claims of working hard. That's not regulation, it's blood-sucking at best.